Daridorexant as a novel pharmacotherapeutic approach in insomnia: a systematic review and meta-analysis

S Dutta, S Singhal, R Shah, J Charan… - Expert Opinion on …, 2023 - Taylor & Francis
Background Insomnia is a multi-factorial disorder with conventional treatment options that
are not satisfactory for many patients. This metaanalysis analyzed the safety and efficacy of …

The pharmacological management of treatment-resistant depression: what does the future hold?

A Serretti - Expert Opinion on Pharmacotherapy, 2023 - Taylor & Francis
A Serretti is or has been a consultant to or has received honoraria or grants unrelated to the
present work from: Abbott, Abbvie, Angelini, Astra Zeneca, Clinical Data, Boheringer, Bristol …

Interplay of environmental and clinical factors in psychiatric disorders

A Serretti - International Clinical Psychopharmacology, 2023 - journals.lww.com
An intriguing interplay is the one between lifestyle habits, stress reactivity, and mental
disorders. Unhealthy lifestyle habits, such as poor diet or sleep, lack of physical activity, and …

Daridorexant, an Orexin Receptor Antagonist for the Management of Insomnia

J Najib, Y Toderika, L Dima - American Journal of Therapeutics, 2023 - journals.lww.com
Background: Insomnia is a common sleep disorder that is diagnosed primarily by patients'
subjective reported symptoms. Daridorexant is a new dual orexin receptor antagonist that …

[PDF][PDF] A comprehensive review of Dual Orexin Receptor Antagonist (DORA), Daridorexant: Novel drug for sleep and related disorders

S Misra - therapy - ijlbpr.com
Sleep disorders are increasing at an alarming rate with insomnia affecting nearly one third of
the world population. The mechanisms of wakefulness and sleep are intricate. The main …